Introduction {#sec1-1}
============

Many pediatric patients receive multiple medications for their treatments and this condition can potentially lead to drug--drug interactions (DDIs) and may further complicate the course of the diseases in pediatrics clinics. As the pharmacokinetics of drugs in pediatric patients is different from adults, the drug interactions in pediatric population require more attention compared with adults ([@ref1]). The changes in excretion and elimination processes may prolong the half-life of metabolized drugs and this may cause toxicity problems ([@ref2]).

Hospitalized patients are at an increased risk of potential DDIs due to the multiple medications prescribed, and their illnesses can also cause physiological changes that may further affect both pharmacokinetic and pharmacodynamic responses ([@ref3]). Drug--drug interactions may cause treatment failure and adverse drug reactions that can complicate the course and clinical picture of diseases severity ([@ref4]).

There are scarce data on DDIs and pharmacokinetics profiles in pediatric population due to ethical and practical limitations ([@ref1], [@ref5]). The results of a pediatric database analysis in the United States showed that approximately half of hospitalized children were exposed to a potential DDI, of which 41% were considered 'major' according to the Micromedex DRUG-REAX classification system ([@ref6]). The prevalence of potential DDIs was also investigated in children admitted to emergency departments and it was reported to be as high as 61% ([@ref7]). Moreover, studies performed on adult populations extrapolated to the pediatric population may result in under or over prediction of the severity of DDIs ([@ref5]).

The aim of this study was to identify the prevalence of potential DDIs in hospitalized pediatric patients, to categorize the main drug classes involved in severe DDIs, and to highlight clinically relevant DDIs in the pediatric population.

Material and Methods {#sec1-2}
====================

This single-center, retrospective, cross-sectional study included pediatric patients aged between 1 week and 18 years, who were hospitalized for more than 24 hours in Haydarpaşa Numune Health Practice and Research Center Pediatrics Clinic between January 2016 and December 2016. One thousand five hundred prescriptions were reviewed during the 12-month study period. Five hundred ten prescriptions included two or more drugs and these prescriptions were included in the study. Prescriptions including topical drugs, electrolytes, vitamins, and insulin were excluded. The drugs administered during hospitalization were retrospectively analyzed after obtaining institutional clinical research ethics committee approval (Document No.: HNEAH-KAEK 2017/KK/53, Date: 24.04.2017). The study was conducted in accordance with the Declaration of Helsinki.

The drugs were further classified according to the anatomical therapeutic chemical (ATC) classification ([@ref8]). Data about demographic characteristics, primary diagnosis and comorbidities, medical prescriptions, and clinical and laboratory features if necessary were collected from the patients' medical records. Diagnostic classifications were performed according to the tenth revision of the International Classification of Disease.

The presence of potential DDIs was identified by using the Lexi-Interact database and categorized according to severity: A (unknown), B (minor), C (moderate), D (major), and X (contraindicated) ([Appendix 1](#T4){ref-type="table"}) ([@ref9]). As A and B interactions were considered as minor, the drugs showing C and D interactions were considered clinically important pDDIs for further analysis. The SPSS statistical software (Version 22, SPSS Inc., Chicago, II, USA) was used for descriptive analysis of the data.

Results {#sec1-3}
=======

The demographic and clinical characteristics of the included patients are summarized in [Table 1](#T1){ref-type="table"}. Nearly half the patients (46%, n=234) were aged under one year and 40% were aged between four weeks and one year.

###### 

Clinical and demographic characteristics of the patients

  Clinical and demographic data   n                       \%
  ------------------------------- ----------------------- ------
  Number of patients              510                     
  Age distribution                                        
   0--4 weeks                     29                      5.7
   \>4 weeks- 1 year              205                     40.2
   \>1--3 years                   72                      14.1
   \>4--6 years                   61                      12.0
   \>6--14 years                  97                      19.0
   \>14 years                     46                      9.1
  Sex (male/female)               256 (50.2)/254 (49.8)   
  Length of stay in hospital,                             
  day (mean±SD)                   5.1±2.0                 
  Length of stay in ICU,                                  
  day (mean±SD)                   2.5±1.0                 

SD: Standard deviation; ICU: Intensive care unit

The most common primary diagnosis was respiratory system diseases (n=297, 58%), followed by infectious (n=68, 13%), urinary system (n=61, 12%), gastrointestinal system (n=42, 8%), central nervous system (n=30, 6%) diseases, and hematologic disorders (n=12, 2.4%).

There were 1498 drugs in 510 prescriptions; 253 of these (49.6%) included 2 drugs, 228 (44.7%) included 3--4 drugs, and 29 (5.6%) included ≥5 drugs. A total of 634 (42%) potential DDIs were idenfied. Among those, 271 (42.7%) were categorized as A, 284 (44.8%) as B, 53 (8.4%) as C and 26 (4.1%) as D. There was no potential risk for X interaction. The distribution of interaction categories according to the number of drugs in prescriptions is presented on [Figure 1](#F1){ref-type="fig"}.

![The distribution of interaction categories according to the number of drugs in prescriptions is presented](TPA-55-30-g001){#F1}

Of the total 1498 administered drugs, 158 of them (10.5%) were involved in potential C and/or D categories. The main drug classes involved in C and/or D interactions were anti-infectives (36%), followed by agents of the central nervous system (19%), respiratory system (16%), endocrinology (13.3%), cardiovascular (9.5%) drugs, non-steroidal anti-inflammatory drugs (NSAIDs) (3.8%), and gastrointestinal system drugs (2.5%). Among the 158 drugs involving in C and/or D interactions, there were 110 different pharmacologically active substances, and 34 different interacting medications were identified ([Table 2](#T2){ref-type="table"}).

###### 

Drug classes specific medications associated with C and/or D interactions, and the frequency of interactions

  Drug classes (frequency of interactions)                                 Specific medications (frequency of interactions)
  ------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-infective drugs (n=57)                                              Clarithromycin (n=37), ceftriaxone (n=4), amikacin (n=3), streptomycin (n=3),
  vancomycin (n=2), rifampicin (n=2), gentamicin (n=1), isoniazid (n=2),   
  meropenem (n=1), cefepime (n=1), colistin (n=1)                          
  Central nervous system drugs (n=30)                                      Levetiracetam (n=8), phenobarbital (n=7), midazolam (n=5), valproic acid (n=3), fentanyl (n=2), clonazepam (n=1), phenytoin (n=1), diazepam (n=1), pheni ramine (n=1), sertraline (n=1)
  Respiratory system drugs (n=25)                                          Salbutamol (n=2), budesonide (n=23)
  Endocrine drugs (n=21)                                                   Methylprednisolone (n=17), prednisolone (n=2), dexamethasone (n=2)
  Cardiovascular system drugs (n=15)                                       Furosemide (n=10), enalapril (n=3), digoxin (n=1), captopril (n=1)
  NSAIDS ([@ref6])                                                         Acetylsalicylic acid (n=1), ibuprofen (n=5)
  Gastrointestinal drugs (n=4)                                             Aluminium hydroxide and magnesium carbonate antacid (n=3), ursodeoxycholic acid (n=1)

NSAID: Non-steroidal anti-inflammatory drugs

Seventy-nine out of 634 potential DDIs (12.5%) were classified as C and/or D interactions. Of the 79 potential DDIs with a severity rating of C and/or D, 34 were unique drug pairs (a specific combination of interacting medication that is counted once). The drug pairs causing C and/or D interactions are presented in [Table 3](#T3){ref-type="table"}.

###### 

Drug classes of clinically significant potential drug-drug interactions

  Drug class (n)                                   Drug                      Potential drug for interaction   Category of interaction   
  ------------------------------------------------ ------------------------- -------------------------------- ------------------------- ---
  Anti-infective (^48^)                            Clarithromycin            Budesonide                       20                        C
  Clarithromycin                                   Methylprednisolone        14                               D                         
  Clarithromycin                                   Dexamethasone             2                                D                         
  Clarithromycin                                   Midazolam                 1                                D                         
  Ceftriaxone                                      Streptomycin              2                                C                         
  Rifampicin                                       Isoniazid                 1                                C                         
  Rifampicin                                       Valproic acid             1                                D                         
  Isoniazid                                        Valproic acid             1                                C                         
  Ceftriaxone                                      Gentamicin                1                                C                         
  Ceftriaxone                                      Amikacin                  1                                C                         
  Cefepime                                         Amikacin                  1                                C                         
  Streptomycin                                     Ibuprofen                 1                                C                         
  Meropenem                                        Valproic acid             1                                D                         
  Vancomycin                                       Colistin                  1                                D                         
  Central nervous system ([@ref13])                Phenobarbital             Levetiracetam                    5                         C
  Phenobarbital                                    Midazolam                 2                                D                         
  Phenytoin                                        Midazolam                 1                                D                         
  Fentanyl                                         Sertraline                1                                C                         
  Fentanyl                                         Pheniramine               1                                D                         
  Diazepam                                         Levetiracetam             1                                C                         
  Midazolam                                        Levetiracetam             1                                C                         
  Clonazepam                                       Levetirecetam             1                                C                         
  Endocrine system ([@ref7])                       Methylprednisolone        Ibuprofen                        3                         C
  Budesonid                                        Furosemide                3                                C                         
  Prednisolon                                      Furosemide                1                                C                         
  Cardiovascular system ([@ref4])                  Furosemide                Enalapril                        2                         C
  Furosemide                                       Digoxin                   1                                C                         
  Furosemide                                       Captopril                 1                                C                         
  Gastrointestinal system ([@ref3])                Aluminium hydroxide and                                                              
  magnesium carbonate antacid                      Amikacin                  1                                C                         
  Aluminium hydroxide and                                                                                                               
  magnesium carbonate antacid                      Prednisolone              1                                D                         
  Aluminium hydroxide and                                                                                                               
  magnesium carbonate antacid                      Ursodeoxycholic acid      1                                D                         
  Respiratory system ([@ref2])                     Salbutamol                Furosemide                       2                         C
  Nonsteroidal anti-inflammatory drugs ([@ref2])   Acetylsalicylic acid      Enalapril                        1                         C
  Ibuprofen                                        Vancomycin                1                                C                         

Clarithromycin was the most common interacting drug with 37 times affecting budesonide (n=20), methylprednisolone (n=14), dexamethasone (n=2), and midazolam (n=1) ([Table 3](#T3){ref-type="table"}). Critical potential DDIs (D category) were detected between rifampicin and valproic acid, meropenem and valproic acid, and between vancomycin and colistin ([Table 3](#T3){ref-type="table"}). The other frequently interacting drug class was the central nervous system drugs including levetiracetam (n=8), phenobarbital (n=7) and midazolam (n=5). The other most commonly interacting medications were budesonide (n=23), methylprednisolone (n=17), furosemide (n=10) and ibuprofen (n=5) ([Table 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Discussion {#sec1-4}
==========

This study evaluated the frequency of clinically important potential DDIs (C and D risk categories) in hospitalized pediatric patients. In terms of severity, most interactions were minor and no potential risk for contraindication was detected. The drug classes and specific medications that have potential for interaction are identified to highlight the importance of these interactions, which may result in the occurrence of adverse drug reactions, noncompliance to treatment, failure in treatment, and increased duration of hospitalization. As irrational drug use is one of the risk factors for the development of adverse reactions, frequently noted potential DDIs should be considered by physicians for patient safety ([@ref10]).

The main risk factor for adverse drug reaction occurrence in the pediatric population is the increase in the number of prescription drugs ([@ref11]). In this study, the number of patients prescribed two or more drugs were 510 among 1500 prescriptions; 253 of these (49.6%) included 2 drugs, 228 (44.7%) included 3--4 drugs, and 29 (5.6%) included ≥5 drugs. The frequency of C and D interactions were the highest among the prescriptions including 3--4 drugs. In line with previous studies, both in adult and pediatric populations ([@ref12], [@ref13]), increased numbers of total daily medications were associated with a greater potential DDI in our study population. These findings indicate that pediatric prescriptions should contain the smallest possible number of medications to prevent possible drug interactions ([@ref13]).

The prevalence of potential DDIs (42%) was found be lower than the reported findings of other studies in pediatric hospitals in Mexico (61%) and Philadelphia (49%), but higher than the prevalence of DDIs found in other pediatric studies (3.8%) ([@ref5]--[@ref7], [@ref14]). This wide variability in the reported prevalence of DDIs in different studies can be explained by the included population, the underlying medical conditions of the involved patients, the study design, and the software used for their identification ([@ref6], [@ref12]). In our study, a total of 634 potential DDIs were identified in all 1498 patients, out of which 8.4% were 'moderate,' 4.1% were 'major,' without any 'contraindicated' pDDIs. This ratio was lower than the results found in another study that reported 57.3% moderate and 18% major DDIs (D and X, respectively) ([@ref15]). Another study reported that contraindicated DDIs occurred in 5%, major DDIs in 41%, moderate DDIs in 28%, and minor DDIs in 11% of all hospitalizations ([@ref6]). Also, it was reported that the ratio of 'contraindicated' DDI was 0.2%, 'serious' DDIs were 7.5%, and 'significant-monitor closely' were 62.8% ([@ref7]). The large difference in the prevalence of clinically important potential drug interactions might be due to the critical medical conditions of pediatric inpatients, which make them more susceptible to the administration of multiple drugs, complex treatment regimens, and care by physicians of different specialties for consultations ([@ref15], [@ref16]). In addition, hospitalized pediatric patients are vulnerable to medication-related issues because of off-label prescribing of drugs, lack of therapeutic profiles for rare drugs, and weight-based dosing strategies. Our study may reflect developments in the practice of physicians over time with previous valuable efforts and their awareness.

In our study, the most common diagnoses were respiratory system diseases, infectious diseases were also commonly encountered in children, and anti-infective agents and drugs used in the respiratory system and central nervous system were the main drug classes involved in C and D interactions. In accordance with previous studies ([@ref2], [@ref13], [@ref17], [@ref18]), the present study revealed that anti-infective agents (36.1%) were the most prescribed agents in pediatric patients. It was followed by central nervous system (19%) and respiratory system drugs (15.8%), which are also associated with clinically significant adverse drug reactions and interactions. It has also been shown that opioids are involved in nearly 25% of all DDIs, followed by anti-infective agents (17%), and neurologic agents (15%), similar to our results ([@ref5], [@ref6]). We found central nervous system drugs (19%) to be the second most common prescribed drugs.

There is a wide range of different consequences that could be predicted according to DDI mechanisms. The results of potential DDIs may be due to pharmacokinetic mechanisms such as induction or activation of the metabolizing enzymes causing a decrease or increase of the serum concentration of the object drug or pharmacodynamic reactions related to receptors, both resulting in additive effects such as hypotension, CNS depression, and adverse effects ([@ref19]).

The results of the current study revealed that the most common potential drug-drug interactions were between clarithromycin and budesonide and methylprednisolone, in terms of the pharmacokinetic interactions. It was reported in another study that frequent potential moderate interactions were also noted between clarithromycin and corticosteroids (10.7%) ([@ref13]). Regarding the concomitant administration of such drugs, their effectiveness may be altered by metabolizing enzyme CYP3A4 inhibition. Therefore, monitoring of drug interactions is especially important in children with asthma attacks. In addition, the rational use of antibiotics is an important issue in our country, where the prescription of antibiotics requires close monitoring for both maintaining efficacy, preventing resistance, and reducing cost. The inhibition or activation of drug-metabolizing enzymes and alterations in gastrointestinal absorption of antibiotics are also the most common mechanisms often associated with antimicrobial interactions ([@ref19]--[@ref21]).

Another important interaction includes the interaction of meropenem (anti-infective agent) with valproic acid, and rifampicin with valproic acid. These interactions may decrease the efficacy of valproic acid. There is a risk of nephrotoxicity with concomitant use of streptomycin with ibuprofen and vancomycin with colistin. Also, concomitant use of ceftriaxone with streptomycin or gentamicin or amikacin may lead to nephrotoxicity due to potential interactions ([@ref9]).

The second most common interaction was found between antiepileptic drugs; phenobarbital-levetiracetam, phenobarbital-midazolam, and also between phenytoin and midazolam. Diazepam-levetiracetam, midazolam-levetiracetam, and clonazepam-levetiracetam interactions may result in increased central nervous system depression and subsequent toxicity.

The cardiovascular drug groups are among the most frequent drugs involved in DDIs ([@ref22], [@ref23]). Hypopotassemia and hypotension may develop as a result of DDIs with the use of different groups of cardiovascular drugs ([@ref24]). In our study, enalapril use with acetylsalicylic acid was also detected in one patient, which may increase the risk of nephrotoxicity. Concomitant use of steroids with diuretic furosemide may also lead to increased hypopotassemia and furosemide use with agents acting on the cardiovascular system such as digoxin and captopril combination lead to digoxin toxicity and an increased hypotensive effect, respectively.

Considering the current profile of interactions, prevention measures should include strategies such as dosage adjustment considering pharmacokinetics, avoidance of group use, observation of the therapeutic response, and clinical monitoring for the early detection of adverse effects ([@ref25]). Identifying and finding the exact cause of common potential DDIs could help physicians to understand clinical situations in which co-administration is acceptable, to motivate them to monitor for potential adverse drug effects, and to adjust dose regimens when adverse drug reactions occur. This requires participation of clinical pharmacologists in the multidisciplinary team, to evaluate the pharmacotherapy of patients, especially in populations with special needs such as pediatrics or geriatrics. Clinical pharmacologists are highly competent on these problems and have a unique insight into the possible mechanism related with drug use ([@ref26]). It is now well known that rational drug use considers the efficacy, safety, suitability, and the cost of medication use during treatment regimens. Consideration to the principles of rational drug use would also prevent the occurrence of many DDIs. This is especially important for pediatric population, in which the pharmacokinetic parameters of medications are very different from the adult population ([@ref27]).

The limitation of this study was that the clinical outcomes related to DDIs are not presented because the data were collected from hospital records and analyzed retrospectively. In addition, the data were collected only from a single dedicated center and the generalization of these results to all centers is relatively hard. The Lexi-Interact program is commonly preferred by Turkish physicians and available in many hospitals due to its accessibility; however, the use of different software could also provide more accurate results ([@ref28]).

The setting of the current study is a tertiary care hospital that is a referral center in Istanbul and reported interactions related to the most commonly prescribed drugs could provide information for other pediatricians. Interactions reported in the present study may alert physicians and lead to alterations in their treatment choices to reduce clinical problems and complications caused by such interactions.

In conclusion, while prescribing medications in the pediatric population, physicians should be aware of potential pharmacodynamic and pharmacokinetic drug interactions and treatment regimens should be adjusted accordingly. Highlighting the possible severe interactions of drug classes may increase the awareness of physicians about patient safety, and the categories of DDIs according to drug classes may help physicians prevent possible clinically significant DDIs.
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###### 

The definition of each risk rating of Lexi-Interact data fields

  Risk rating   Action              Description
  ------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A             No Interaction      Data have not demonstrated either pharmacodynamic or pharmacokinetic interactions between the specified agents
  B             No action needed    Data demonstrate that the specified agents may interact with each other, but there is little to no evidence of clinical concern resulting from their concomitant use
  C             Monitor therapy     Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The benefits of concomitant use of these two medications usually outweigh the risks. An appropriate monitoring plan should be implemented to identify potential negative effects. Dosage adjustments of one or both agents may be needed in a minority of patients.
  D             Modify regimen      Data demonstrate that the two medications may interact with each other in a clinically significant manner. A patient-specific assessment must be conducted to determine whether the benefits of concomitant therapy outweigh the risks. Specific actions must be taken in order to realize the benefits and/or minimize the toxicity resulting from concomitant use of the agents. These actions may include aggressive monitoring, empiric dosage changes, choosing alternative agents.
  X             Avoid combination   Data demonstrate that the specified agents may interact with each other in a clinically significant manner. The risks associated with concomitant use of these agents usually outweigh the benefits. These agents are generally considered contraindicated.
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[^1]: **The known about this topic**

    Considering the principles of rational drug use which considers the efficacy, safety, suitability and the cost of medication during treatment regimens would also prevent the occurrence of many drug-drug interactions. This is especially important for pediatric population, where the pharmacokinetic parameters of the medications are very different from adult population. There is scarce data on drug-drug interactions and pharmacokinetics profiles in pediatric population due to ethical and practical limitations.

[^2]: **Contribution of the study**

    The results of this study give detailed information about the abundance of potential clinically significant drug-drug interactions and their mechanisms in a Pediatric clinic. The studies performed on adult population extrapolated to the pediatric population may result in under or over prediction of the severity of drug-drug interactions. Therefore the prevalence of potential drug-drug interactions in hospitalized pediatric patients and main drug classes involved in severe potential drug-drug interactions in pediatric population are presented.
